Candel Therapeutics Statistics
Total Valuation
CADL has a market cap or net worth of $284.16 million. The enterprise value is $283.63 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CADL has 32.48 million shares outstanding. The number of shares has increased by 3.83% in one year.
| Current Share Class | 32.48M |
| Shares Outstanding | 32.48M |
| Shares Change (YoY) | +3.83% |
| Shares Change (QoQ) | +7.15% |
| Owned by Insiders (%) | 13.84% |
| Owned by Institutions (%) | 17.72% |
| Float | 19.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18
| Current Ratio | 1.18 |
| Quick Ratio | 1.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.98 |
Financial Efficiency
Return on equity (ROE) is -1,344.47% and return on invested capital (ROIC) is -95.44%.
| Return on Equity (ROE) | -1,344.47% |
| Return on Assets (ROA) | -62.08% |
| Return on Capital (ROIC) | -95.44% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 42 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +710.19% in the last 52 weeks. The beta is -0.94, so CADL's price volatility has been lower than the market average.
| Beta (5Y) | -0.94 |
| 52-Week Price Change | +710.19% |
| 50-Day Moving Average | 5.49 |
| 200-Day Moving Average | 6.10 |
| Relative Strength Index (RSI) | 61.32 |
| Average Volume (20 Days) | 9,654,548 |
Short Selling Information
The latest short interest is 2.18 million, so 6.71% of the outstanding shares have been sold short.
| Short Interest | 2.18M |
| Short Previous Month | 2.10M |
| Short % of Shares Out | 6.71% |
| Short % of Float | 11.11% |
| Short Ratio (days to cover) | 7.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | -25.57M |
| Operating Income | -35.55M |
| Pretax Income | -37.37M |
| Net Income | -52.20M |
| EBITDA | -34.55M |
| EBIT | -35.55M |
| Earnings Per Share (EPS) | -$1.74 |
Full Income StatementBalance Sheet
The company has $16.56 million in cash and $16.02 million in debt, giving a net cash position of $535,000 or $0.02 per share.
| Cash & Cash Equivalents | 16.56M |
| Total Debt | 16.02M |
| Net Cash | 535,000 |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | -15.26M |
| Book Value Per Share | -0.47 |
| Working Capital | 2.82M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.63 million and capital expenditures -$60,000, giving a free cash flow of -$28.69 million.
| Operating Cash Flow | -28.63M |
| Capital Expenditures | -60,000 |
| Free Cash Flow | -28.69M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |